Professor Donald Henderson, sketched by R 5-5 the Burroughs Wellcome visiting professor, Donald Henderson (Figure 1) , who received the Jenner Medal.
AFTER SMALLPOX ERADICATION-WHAT NEXT?
Towards the end of the last century, there was considerable optimism about the possibility of eradicating disease. When the concept became popular in 1888, the eradication of tuberculosis was urged. Eradication of contagious pleuropneumonia in the USA in 1892 led to hope that global eradication could be soon achieved for this and other diseases. Elimination of yellow fever from Havana in 1901 was followed by a confident campaign to eradicate hookworm in the USA: its failure was acknowledged in 1922. A US attempt to eradicate yellow fever commenced with similar optimism in 1907; by 1933 it too had failed. The global attack on malaria, launched in 1955, was abandoned in 1969. Optimism was nevertheless still high in the 1960s: in 1967 a Centers for Disease Control epidemiologist was quoted as confidently predicting that measles could be eradicated within a year.
By the time smallpox was successfully eradicated-the official date was 9 December 1979-a more sober and considered approach to eradication had been accepted. This included more precision about definitions, and a better understanding of the pathogenesis and natural history of the diseases.
Professor Norman Noah distinguishes eradication from elimination as follows. Eradication is 'the reduction of the world-wide incidence of the disease to zero, as a result of deliberate efforts, obviating the necessity for further control measures'. Elimination is 'the disappearance of a disease in humans although the infectious agent still remains at large, or the eradication of disease from a single country, continent or other limited geographical area'.
Thus, for many infectious diseases, elimination is currently a more realistic target. It can be considered on three levels. First, the disease may remain, but undesirable clinical manifestations are eliminated; an example is the use of ivermectin to control the blindness caused by onchocerciasis. Secondly, transmission may be eliminated but late, non-infectious phases of the disease remain, as in yaws. Thirdly, the manifestations of a disease may be controlled so that it no longer represents a public health hazard; this has been achieved for leprosy. Examples of elimination in the UK are malaria, rabies, brucellosis, bovine tuberculosis and poliomyelitis.
Why have some eradication campaigns failed? In the case of hookworm, treatment decreased severity but did not eliminate the disease, so that reinfection occurred. The yellow fever campaign failed because the cycle in non-human primates was not recognized. Yaws eradication, launched in 1955, failed through the existence of asymptomatic latent cases. While the natural history of malaria was well documented by the time the global campaign started, with high hopes of success, several factors contributed to the breakdown of the eradication attempt. These included the resistance of vectors to insecticides, the resistance of the parasites to therapy and the unexpected diversity and tenacity of some vectors. Administrative shortcomings and rising costs finally doomed the campaign. The malaria story demonstrates the still current problem of the rising costs of an eradication campaign, and the loss of interest when early success is not achieved.
Candidates for eradication in the 19905
Between 1989 and 1992 the Internal Task Force on Disease Eradication (lTFDE) screened 94 diseases as potential candidates for eradication and examined 29 in depth. Of these, six diseases were judged eradicable and seven eliminable. The six infectious diseases that the ITFDE thought could be eradicated were dracunculiasis, polio, rubella, mumps, cysticercosis, and lymphatic filariasis. Obstacles to eradication were identified, including sylvatic reservoirs (as for yellow fever), environmental reservoirs (cholera), the need for multiple dose vaccines (diphtheria, whooping cough), and heat lability of vaccines (yellow fever). For other diseases, the fact that the diagnostic tests were slow and laborious was a serious deterrent (e.g. tuberculosis, diphtheria, aSCarIaSIS, leprosy). Highly infectious diseases such as measles and whooping cough posed another problem, as did diseases where there was known latency of the virus (e.g. varicella zoster).
Dracunculiasis (guinea worm infection)
Dracunculiasis is a disease with favourable characteristics for eradication. It is easily diagnosed; it has a predictable seasonal pattern; man is the only host for the parasite; and the disease is spread only by drinking contaminated water. An obvious factor against eradication is that there is no immunity to the disease and no vaccine can be produced. There is also a long incubation period. Last but not least, the disease has a low charisma. The public perception of a disease is a crucial factor in the funding and success of an eradication campaign.
Nevertheless, in the case of dracunculiasis, considerable progress has been made. In 1980 it was endemic in 16 countries; it is now endemic in only nine areas including Niger, Nigeria, Sudan, Burkino Faso, the Ivory Coast, Mali, Togo and Uganda. There have been no cases in Pakistan since October 1993 and none in Kenya since April 1994. The target for eradication is now the year 2000.
Tetanus
Despite the availability of tetanus toxoid, neonatal tetanus caused an estimated 390000 deaths in 1994. Only O. 3% deaths occur in Europe; 49% are in South East Asiaand 29% in Africa. The strategy for tetanus is elimination, aiming to reduce the incidence to less than one easel 1000 live births in each healthy district of every country. Currently the incidence in endemic areas is 5/1000 live births. To eliminate tetanus, more than 80% of infants need to be protected at birth. Maternal vaccination is only part of the strategy, which includes clean delivery and cord care practice, training of birth attendants, surveys of tetanus toxoid coverage and quality checks on the tetanus toxoid itself. Priorities for the elimination of neonatal tetanus include the identification of foci of increased incidence, so that staff and resources can be mobilized for intensive immunization activity. Another key factor is the improvement of surveillance so that all cases are detected and investigated.
Leprosy
The prospects of eliminating leprosy by 2000 are promising.
In this case the definition is important, including only those cases known to be on drug therapy. Factors favouring the eradication of leprosy include the lack of animal reservoirs and the absence of long-term carriers. It is easily recognized and there seems to be no subclinical infection; also the average age of infection is high and immunity is lifelong. The uneven distribution may also be a hopeful factor; 92% of the cases occur in only 25 countries of which five countries have 80% of the cases.
Candidates for elimination
The seven disease processes judged eliminable by the ITFDE are: blindness caused by onchocerciasis; urban rabies; transmission of yaws; transmission of hepatitis B; transmission of neonatal tetanus; blindness secondary to trachoma; and iodine deficiency disorders. The preconditions stated by Yekutiel 3 for the elimination of an infectious diseaseinclude the availabilityofa simple and cheap tool! control measure to break the transmission, effective case detection and surveillance, socio-economic importance (charisma again), a specificreason for the eradication (rather than control) of the disease, the availability of resources and appropriate socio-ecological conditions. However, there are no hard and fast rules about elimination of disease. Every disease must be considered on its merits. Much was learned from the smallpox programme. In 1987 Donald Henderson stressed that WHO leadership was essential and that the programme must be targeted, time limited, with specificfunding, and with full-time technical staff. The main lessons were as follows:
• WHO leadership and universal political commitment • Special Programme needs to be: targeted, time-limited, funds specially allocated, full-time technical staff • Community-wide services in addition to traditional health care system • Explicit goals and objectives more likely to gain community support and resources
• Efficiency savings may be made • Collegiate structure of independent national programmes • Capable professional staff-leadership, flexibility, resources, motivation, experience, understanding of strategy and tactics • Logistics: transport, vaccine availability, administration of funds • Operational objectives rather than specified methodology: vaccination and surveillance • Quality control important throughout • Problem oriented research • Believable certification of eradication
GLOBAL ERADICATION OF POLlO-WHEN AND HOW?
The tombstone of Karl Marx in Highgate Cemetery is engraved with the words 'the philosophers have only interpreted the world in various ways; the point is to change it'. The global picture of poliomyelitis is a good example of this change. For official global eradication, the requirements are that there will be no cases due to wild polio virus, that wild polio virus transmission will cease, and that no wild polio virus will be found. The basic strategies for this include four important points: routine immunization-in all areas, all populations; national immunization days (NIDs); acute flaccid paralysis (AFP) and virus surveillance; and 'mopping up' -pursuing the campaigns once near-elimination has been achieved.
National immunization days have been hugely successful in Brazil; the average child there now receives more than 10 doses of oral polio virus. There has been a rapid increase in the global coverage of oral polio virus since 1985, when the proportion vaccinated was 48%. After a gradual rise to 74% by 1989, a UNICEF exercise in 1990 produced a 10% increase. However, the 85% vaccination achieved in 1990
has not yet been exceeded, the figure for 1995 being 83%. There is also a wide variation in the coverage by WHO region: for example, in Africa it is only 58%, whereas the proportion vaccinated in Europe is now 89%.
National immunization days have been introduced with great success in many countries. In 1988, 16 countries held NIDs. These increased by 1995 to cover 62 countries, and 88 countries are holding such days in 1996. This approach has been especially successful in India and Asia.
The role of acute flaccid paralysis surveillance
AFP surveillanceis an important factor in monitoring the success of campaigns. Many Africancountries have no such surveillance. There tends to be a pattern where an initial increase in cases is seen when the surveillance is begun. However, there is a continuing rise in the countries reporting no casesof paralysis. In 1988,35251 AFP caseswere reported to WHO; in 1995, 6217 caseswere reported. InSouth EastAsia,NIDs havebeen a critical factor in reducing cases of paralysis, which fell from 25711 in 1988 to 3398 in 1995.
Mopping up
In considering the benefits of polio eradication, it is not only the reduction in diseaseand disabilitythat tips the balance: countries can also make large financial savings on, for example, the cost of vaccine. However, the cost of such campaigns is high, particularly for the purchase of oral polio vaccine. In endemic countries, 80% of the costs have to be met by the countries themselves. However, once polio was eradicated, attention could turn to the control of measles, neonatal tetanus, and other infections. Laboratory networks and more efficientsurveillance would also benefit from a diversion of funds away from polio, following its eradication.
In Europe subjects of concern are the vulnerable borders of the eastern Mediterranean and the issue of vaccine virus transmission.
MEASLES ELIMINATION-FACT OR FANTASY?
The options for controlling measles range from containment, where the morbidity of measles has been reduced to an 'acceptable level' in a target population, to elimination, where no endemic disease will be present in the population; and finally to eradication-that is, global extinction. Containment of measles is not acceptable because it is too difficult to get the right balance. Any model of measles control must include the concept of vaccine failure. With the decline of maternal antibodies in the first months of life vaccine failure and failures to vaccinate give rise to a susceptible population. Even of those vaccinated, 5%-10% will remain non-immune.
Where a substantial proportion of the children are not immune, primary and secondary schools provide the main opportunity for measles transmission. The reproduction number-the number of secondary cases generated by a primary case-can be used to examine age specific susceptibility. Where R is > 1, the number of cases will tend to increase. Where R is < 1 the number of cases clecreases.
In the Americas, the measles elimination strategy includes three important points:
• Catch up-a 'one time only' vaccination • Keep up-routine services for those aged 12-23 months aiming for 95% coverage of the birth cohort • Follow up--maintaining the interruption of transmission particularly in the ages 1-4
With this strategy 93% coverage has been achieved in Latin America and there has been a 97% reduction in cases. In England and Wales, measles was tackled by a major campaign in the autumn of 1994. Measles vaccine was first introduced in 1968 but uptake was poor and the virus continued to circulate. When the MMR (measles,mumps, rubella) vaccine became part of the immunization schedule in 1988, there was a striking decrease in cases and unvaccinated older children no longer acquired the disease. The reproduction number for measles was about two, suggesting the potential for resurgence. In November 1994, 7. 1 million children aged between 5 and 16 years were offered the vaccine. ByDecember 1994, 92% of this target population had been immunized. A key feature of the campaignwas follow-up measlessurveillance by saliva testing of all notified cases, serology, and molecular epidemiology. The campaign produced the desired fall in measles susceptibility as measured by the comprehensive saliva testing and serological surveillance.
However, although much reduced, measles was not eliminated in England and Wales. By molecular epidemiology, circulating genotypes from abroad were identified, including viruses from Italy, Portugal, Pakistan and Iran. With a current estimated reproduction number of 0.7 to 0.8, there is still a 10% risk of a large outbreak in the UK as a result of imported cases of measles. To avoid 'R' rising above the epidemic threshold the required strategy includes giving a second dose of the vaccine at the age of 4 years and having regular campaigns. A single dose of the vaccine cannot be relied upon.
The future strategy for measles
As the WHO has stated, 'the challenge now is to maintain interruption'. Measles still causes more deaths than any other of the Expanded Programme on Immunization's target diseases. Critical questions include: (1) is the current vaccine adequate; (2) is the strategy appropriate; and (3) can the resources and political will be generated? The answers to (1) and (2) seem to be yes. The answer to (3) is more doubtful. France, Germany and Italy have low coverage of measles vaccine and little enthusiasm about raising vaccination levels. Another issue raised in discussion was whether we will have to contemplate the problem of outbreaks in the elderly as the age distribution of susceptibles alters. Will measles vaccination be a requirement for entry into n~rsing homes in 30 years' time?
THE FUTURE
Experience of implementing widespread campaigns has inspired a number of ingenious inventions to make vaccination safer. These include auto-destruct syringes, vaccine vial monitors that change colour if the temperature range is exceeded, and improvements in maintaining the cold chain with appropriate refrigerated containers. The cost of these campaigns in developing countries will dominate increasingly in the future. One strategy is to maintain price differentials for vaccine so that their cost is lower in developing countries, with the development costs of new vaccines being met by the richer countries.
Expanded programme on immunization
Future vaccines may include agents against TB, malaria, HIV, pneumococcal disease, Haemophilus infiuenzae and rotavirus. Delivery systems are an important factor in the success of campaigns and in the future these will involve development of multiple antigens, slow release vaccines, use of the aerosol route, jet guns, safer syringes, and associated diagnostic tests. The constraints of these programmes include the depressing failure when goals are not met, the prospect of failures in vaccine supply, funding problems ('donor fatigue'), civil unrest and natural disasters. The challenge is to extend and maintain immunization services while at the same time introducing new vaccines and new strategies. The challenge is all the more daunting when the issue of litigation is considered. The future dilemma may be that vaccine manufacturers will not feel confident that the high cost of investment will produce sufficient returns.
The perspective of the past can show us what the future may hold for vaccination. Why did eradication of smallpox take so long? Variolation with cowpox was known well before Jenner's famous work. An eighteenth century variolator named Sutton charged up to £20 for each inoculation and to his shame kept the procedure secret. The vaccine itself was a barrier to eradication: until the late 1800s the main method was arm-to-arm transfer, inevitably carrying a risk of transferring other diseases such as hepatitis and syphilis. While this was eventually resolved by the production of a vaccine, the vaccine was heat labile, limiting its widespread use. Not until the 1950s was freeze drying developed to increase the vaccine stability, allowing up to 6 months' storage at 4°-5°C.
History has shown vaccines to be an extremely cost effective public health measure, yet every country could afford to invest more in vaccine development. Diseases for which vaccines could possibly be developed in the future include rheumatoid arthritis, multiple sclerosis and carcinoma of the cervix. There is a contrast between the apparent surfeit of riches of our modern array of vaccines and the slow progress in making vaccines more effective; a simple example is the need to administer several vaccines in a single carrier. In short, we urgently need new initiatives to speed up the progress of vaccination. In the words of Donald Henderson 'the time is late and we need to get at the business'. .
